Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal...( LAIYANG China May 18 Asia-FirstCa...),Health

LAIYANG, China, May 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (''Jiangbo'' or the ''Company''), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.

    Third Quarter of Fiscal Year 2009 Highlights
    -- Total revenue, which reflects newly associated expense restructuring,
       was $25.7 million, compared to $28.1 million in the corresponding
       quarter of 2008
    -- Gross profit was $18.9 million, compared to $21.8 million in the
       corresponding quarter of 2008, and gross margin was 73.4% compared to
       77.4% in the corresponding quarter of 2008
    -- Operating income was $13.3 million, a 53.6% increase from $8.7 million
       for the three months ended March 31, 2008
    -- Net income was $8.9 million, or $0.44 per fully diluted share, up from
       $4.5 million, or $0.46 per fully diluted share, for the three months
       ended March 31, 2008
    -- Non-GAAP adjusted net income was $10.0 million, or $0.97 per weighted
       average share for the three months ended March 31, 2009, up 66.5% from
       non-GAAP adjusted net income of $6.0 million, or $0.61 per weighted
       average number of shares, for the quarter ended March 31, 2008
    -- Acquired Shandong Hongrui Pharmaceutical Factory ("Hongrui") for
       approximately $11.2 million consisting of RMB58.6 million in cash
       (approximately $8.6 million) and 643,651 shares of Jiangbo's common
       stock amounting to approximately $2.6 million
    -- Obtained the legal rights to manufacture and distribute Hongrui's 22
       Traditional Chinese Medicines
    -- Restructured its sales network to distribute products through 28 large
       regional distributors
    -- Changed the corporate name from Genesis Pharmaceuticals Enterprises,
 
'/>"/>
SOURCE  Jiangbo Pharmaceuticals, Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Related medicine news :

1. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
2. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
3. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
4. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
5. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
6. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
8. MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
9. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
11. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results